Overview

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Status:
Completed
Trial end date:
2018-06-14
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the safety and tolerability of subcutaneous (SC) and intravenous (IV) doses of evinacumab in healthy Japanese and Caucasian subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals